CanSino Biologics Inc. ("CanSinoBIO"; SSE: 688185, HKEX: 06185) has been invited to share the practices of innovative vaccine ...
With a budget of up to $20m, the collaboration will establish scalable, rapid manufacturing for recombinant-protein vaccines.
PRESS RELEASE Strategic research collaboration to advance MTx’s recombinant polyclonal IgG technologyAgreement includes R&D funding for ...
The COVID-19 pandemic highlighted an urgent need for efficient, durable, and widely accessible vaccines. This prompted ...
YONGIN, South Korea, Nov. 3, 2025 /PRNewswire/ -- GC Biopharma, a leading global pharmaceutical company based in South Korea, announced today that the Phase 2 clinical trial results for its anthrax ...
Cervical cancer is the only cancer that is vaccine-preventable and curable, but the United States is lagging in its efforts to meet the World Health Organization's 2030 targets to effectively ...
YONGIN, South Korea, Dec. 8, 2025 /PRNewswire/ -- GC Biopharma (006280.KS), a leading global biopharmaceutical company, today announced the first shipment of BARYTHRAX inj., the world's first ...
The Coalition for Epidemic Preparedness Innovations (CEPI) and Samsung Biologics (KRX: 207940.KS), a leading contract ...
In this free webinar, learn how recombinant insulin improves viral production across diverse vaccine platforms. Attendees will gain insight into the role of recombinant trypsin in efficient cell ...
The vaccine maker’s shots involve the successful Covid vaccines’ RNA technology. Health Secretary Robert F. Kennedy Jr. has ...
Two and a half years after Sanofi unveiled to investors a revamped strategy to create an mRNA seasonal flu vaccine, Fierce Biotech has learned that the French pharma has put this pipeline on ice.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results